Atorvastatin

Catalog No.S5715

For research use only.

Atorvastatin is a lipid lowering agent. It is a competitive inhibitor of hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase, the rate-determining enzyme in cholesterol biosynthesis via the mevalonate pathway. Atorvastatin activates autophagy.

Atorvastatin Chemical Structure

CAS No. 134523-00-5

Selleck's Atorvastatin has been cited by 10 Publications

Purity & Quality Control

Choose Selective HMG-CoA Reductase Inhibitors

Biological Activity

Description Atorvastatin is a lipid lowering agent. It is a competitive inhibitor of hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase, the rate-determining enzyme in cholesterol biosynthesis via the mevalonate pathway. Atorvastatin activates autophagy.
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HEK293 MmD0SpVv[3Srb36gZZN{[Xl? NIfndY1VWF:WUlHOV3BQWlSHUkqgeZB1[WunIHnuJG9CXFBzQkGt[ZhxemW|c3nu[{BJTUt{OUOgZ4VtdHNuIFvtQVEzNjUQvF2= M4Lq[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF3OUewO|k6Lz5zNUm3NFc6QTxxYU6=
L6 MYTGeY5kfGmxbjDhd5NigQ>? Mlq5TY5pcWKrdHnvckBw\iClaH;s[ZN1\XKxbDDzfY51cGW|aYOgbY4hemG2IFy2JINmdGy|IHHzd4V{e2WmIHHzJIlv[2:{cH;yZZRqd25ib3[gX|E1S12jY3X0ZZRmKGmwdH:gZ4hwdGW|dHXyc4wtKEmFNUC9NE4xPzkQvF2= Mo\iQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh2MUKzNVcoRjF6NEGyN|E4RC:jPh?=
C2C12 NUDKW3V1TnWwY4Tpc44h[XO|YYm= MX2xJJVO NWfTWppoUW6mdXP0bY9vKG:oIHPlcIwh\GmoZnXy[Y51cWG2aX;uJIlvKG2xdYPlJGMzSzF{IHPlcIx{KGG|c3Xzd4VlKGG|IH35c5NqdiCqZXH2fUBkcGGrbjDlfJBz\XO|aX;uJIF1KDFidV2= NUL1R2JkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCwPFE5PTVpPkKwNFgyQDV3PD;hQi=>
HepG2 MV;GeY5kfGmxbjDhd5NigQ>? M1PPTFEhfU1? MXrVdJJm\3WuYYTpc44hd2ZiTFTMJJJm[2WydH;yJIV5eHKnc4Ppc44hcW5iaIXtZY4hUGWyR{KgZ4VtdHNiYYSgNUB2VSCrbjDwdoV{\W6lZTDv[kBCWkhvc4DlZ4lncWNic3nSUmE> NVLMemdMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCzOVYxQThpPkKwN|U3ODl6PD;hQi=>
HEK293 M{LQcWZ2dmO2aX;uJIF{e2G7 NF65dWpC[3Srdnn0fUBifCCqdX3hckBtcX[ncjDPRXRROUJ|IHX4dJJme3OnZDDpckBJTUt{OUOgSoxxNUmwIHPlcIx{NCCNbU2wMlc{|ryP NVXTPVg{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK1OFExPjhpPkKyOVQyODZ6PD;hQi=>
HEK293 NWTKU2E3TnWwY4Tpc44h[XO|YYm= Mm\3RYN1cX[rdImgZZQhcHWvYX6gcIl3\XJiT1HUVFFDOSCneIDy[ZN{\WRiaX6gTGVMOjl|IF\sdE1KdiClZXzsd{whU21;MD63O:69VQ>? NXLxd5N{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK1OFExPjhpPkKyOVQyODZ6PD;hQi=>
HEK293 NH\he5FHfW6ldHnvckBie3OjeR?= M1L1c2FkfGm4aYT5JIF1KGi3bXHuJIxqfmW{IF;BWHAzSjFiZYjwdoV{e2WmIHnuJGhGUzJ7MzDGcJAuUW5iY3XscJMtKEuvPUKuPFTPxE1? MkjmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ3NEGwOlgoRjJ{NUSxNFY5RC:jPh?=
HEK293 MlK3SpVv[3Srb36gZZN{[Xl? NWL1OGM6UW6qaXLpeIlwdiCxZjDPRXRROUJzIDj1cotvd3ewIH;ybYdqdiliZYjwdoV{e2WmIHnuJGhGUzJ7MzDj[YxteyC3c3nu[{Bme3S{YXTpc4wuOTekZYThMYdtfWO3cn;ubYRmKHO3YoP0doF1\SxiSVO1NF0xNjcQvF2= M{KwT|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NUi3PVg3Lz5{MkW4O|k5PjxxYU6=
HEK293 MVrGeY5kfGmxbjDhd5NigQ>? MoPxTY5pcWKrdHnvckBw\iCRQWTQNWIyKCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIFjFT|I6OyClZXzsd{B2e2mwZzDwbZRifmG|dHH0bY4he3Wkc4TyZZRmNCCLQ{WwQVAvQM7:TR?= NVm5XnpRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK1PFc6QDZpPkKyOVg4QTh4PD;hQi=>
HEK293 MlT1SpVv[3Srb36gZZN{[Xl? NFnEcYNKdmirYnn0bY9vKG:oIF;BWHAySjFiKIXub45wf25ib4Lp[4lvMSCneIDy[ZN{\WRiaX6gTGVMOjl|IHPlcIx{KHW|aX7nJIV{fHKxbnWtN{1{fWyoYYTlJJN2[nO2cnH0[UwhUUN3ME2xMlbPxE1? M4rW[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NUi3PVg3Lz5{MkW4O|k5PjxxYU6=
hepatocytes NEKwVZdHfW6ldHnvckBie3OjeR?= M4DxOlAvOSC2bzCxNEB2VQ>? MkDQeZAhfG9iOUCgcYlvew>? M{\NUWRzfWdibXX0ZYJwdGm|bTDpckBUeHKjZ4XlMWRif2yneTDyZZQhcGWyYYTvZ5l1\XNiYYPz[ZN{\WRicHXyJFExLzZiY3XscJMh[XRiMD6xJJRwKDFyIIXNJJVxKHSxIEmwJI1qdnNiYomgcYVlcWFvbH;zd{Bu\XSqb3SsJGtuRTBwNEROwG0> NVHNOJZkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK1PVMxOzhpPkKyOVk{ODN6PD;hQi=>
hepatocytes M{DqUmZ2dmO2aX;uJIF{e2G7 MnfzNE4yKHSxIEGwJJVO NEDkeGl2eCC2bzC5NEBucW6| MYnEdpVoKG2ndHHic4xqe21iaX6gV5Bz[We3ZT3EZZdt\XlicnH0JIhmeGG2b3P5eIV{KGG|c3Xzd4VlKHCncjCxNEc3KGOnbHzzJIF1KDBwMTD0c{AyOCC3TTD1dEB1dyB7MDDtbY5{KGK7IHPvcpZmdnSrb37hcEBie3OjeTygT40:OS5|zszN NF;LdXk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkW5N|A{QCd-MkK1PVMxOzh:L3G+
A549 M1PWVWN6fG:2b4jpZ4l1gSCjc4PhfS=> MnTHO|IhcHK| NVraSpFRS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTV2OTDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVgvP87:TR?= NX\uc4FSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1O|A2PDJpPkKzOVcxPTR{PD;hQi=>
HS68 M1[4O2N6fG:2b4jpZ4l1gSCjc4PhfS=> MnqyO|IhcHK| MYHDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIV|Y5KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MkKuO:69VQ>? MoS2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3N{C1OFIoRjJ|NUewOVQzRC:jPh?=
MEF M4fSemN6fG:2b4jpZ4l1gSCjc4PhfS=> MlnnO|IhcHK| NV62ZVJ{S3m2b4TvfIlkcXS7IHHnZYlve3RibX;1d4UhVUWIIHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9N|AvP87:TR?= MnLnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3N{C1OFIoRjJ|NUewOVQzRC:jPh?=
HepG2 NX\VN4ppTnWwY4Tpc44h[XO|YYm= NY\XTJBDOTBidV2= Mn\CTY5lfWO2aX;uJI9nKFOURVLQNkBu[XS3cnH0bY9vKGmwIHj1cYFvKEincFeyJINmdGy|IHH0JFExKHWPIHHmeIVzKG:4ZYLubYdpfCCrbnP1ZoF1cW:wIHL5JIludXWwb3Lsc5Qh[W6jbInzbZM> MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjd6NEmzOkc,OjZ5OES5N|Y9N2F-
human red blood cells NFj0fJlCdnSrcHzhd41w\GmjbDDhd5NigQ>? MlfHOFghcHK| M3v4V2FvfGmybHHzcY9lcWGuIHHjeIl3cXS7IHHnZYlve3RiY3jsc5JweXWrbnWtdoV{cXO2YX70JHBt[XOvb3TpeY0h\mGuY3nwZZJ2dSCZMjDpcoZm[3SnZDDpckBpfW2jbjDy[YQh[myxb3SgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KFO\QmKgeIV{fCxiSVO1NF0yOC5|zszN M2\1d|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4OUi4N|A{Lz5{Nkm4PFMxOzxxYU6=
Hep3G M{n4[2Z2dmO2aX;uJIF{e2G7 NHvlXHgzPSC3TR?= M{\SdFQ5KGi{cx?= MV\Jcohq[mm2aX;uJI9nKEiPRzDDc2EhemWmdXP0ZZNmKGmwIHj1cYFvKEincEPHJINmdGy|IHHzd4V{e2WmIHHzJIlv[3KnYYPlJIlvKEyGTDDy[YNmeHSxcjDlfJBz\XO|aX;uJIF1KDJ3IIXNJIlv[3WkYYTl[EBnd3JiNEigbJJ{KGK7IHntcZVvd2[udX;y[ZNk\W6lZTDt[ZRpd2R? Mn23QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzFyMEWzOlcoRjNzMEC1N|Y4RC:jPh?=
A549 NFP6OnhHfW6ldHnvckBie3OjeR?= NGjnO|RT\WS3Y4Thd4UhSWO2aY\peJkhSXO|YYm6JHRp\SCKTVfSJIFkfGm4aYT5JJdieyCyZYLmc5Ju\WRidYPpcochUE2JLVPvRUBz\WS3Y4Thd4Uh[XO|YYmgb4l1KG[{b32gV4lodWFvQXzkdolkcCC5aYToJJRp\SCqdX3hckBz\WOxbXLpcoFvfCCycn;0[YlvKG:{IEGwNEDPxGdidH;0ZYwh[2WubDDsfZNifGW|IH\yc40hSTV2OTDj[Yxtey5iTH;2ZZN1[XSrbjD3ZZMhfXOnZDDhd{BiKHCxc3n0bZZmKGOxboTyc4wtKGGwZDDTRWhCKGG|IHGgcoVo[XSrLDDJR|UxRTBwMEGxOu69VQ>? MnrvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQ5Py9pPlPoSW1DVDxxYU6=
Assay
Methods Test Index PMID
Growth inhibition assay Cell viability 24815071
Western blot PDX-1 / BETA2 / NeuroD 30863781

Protocol (from reference)

Solubility (25°C)

In vitro

DMSO 100 mg/mL
(179.0 mM)
Ethanol ''-1 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 558.64
Formula

C33H35FN2O5

CAS No. 134523-00-5
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC(C)C1=C(C(=C(N1CCC(CC(CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04915183 Not yet recruiting Drug: Atorvastatin|Other: Placebo Hearing Loss|Head and Neck Cancer National Institute on Deafness and Other Communication Disorders (NIDCD)|National Institutes of Health Clinical Center (CC) January 18 2022 Phase 3
NCT04388501 Completed Drug: Milvexian|Drug: Atorvastatin Healthy Janssen Pharmaceutica N.V. Belgium June 7 2021 Phase 1

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Atorvastatin | Atorvastatin supplier | purchase Atorvastatin | Atorvastatin cost | Atorvastatin manufacturer | order Atorvastatin | Atorvastatin distributor